Back

Plasma transthyretin fractions in transthyretin cardiac amyloidosis patients undergoing tafamidis treatment

31 August 2025 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Shedding light on transthyretin cardiac amyloidosis Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Vincenzo Castiglione

Fondazione Toscana Gabriele Monasterio, Pisa (Italy)

7 More presentations in this session

Presentation thumbnail
Predictors and outcomes of amyloid cardiomyopathy caused by transthyretin V30 mutation
Doctor M. Pereira Santos (Porto, PT)
Abstract Slides Video
Presentation thumbnail
Nutritional status and its impact on transthyretin cardiac amyloidosis: unraveling connection
Mrs P. Lujan Garcia (Las Palmas de Gran Canaria, ES)
Abstract Slides Video
Presentation thumbnail
Lifetime physical and athletic activity as novel risk factors in the development of wild-type transthyretin amyloid cardiomyopathy - a multicenter cohort study
Doctor N. Schwegel (Graz, AT)
Abstract Slides Video
Presentation thumbnail
A review of routine bone scintigraphy reports for identification of incidental myocardial tracer uptake indicating cardiac amyloidosis
Mr D. Hutt (London, GB)
Abstract Slides Video
Presentation thumbnail
Unraveling gender differences in hereditary transthyretin amyloidosis: insights from the REACT registry
Miss L. Freire (Sao Paulo, BR)
Abstract Slides Video

Access the full session

Session thumbnail
Shedding light on transthyretin cardiac amyloidosis

The Event

Event poster

ESC Congress 2025

31 August 2025 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Tafamidis for the treatment of transthyretin cardiac amyloidosis (ATTR-CM) - Real-world data from a tertiary center.
thumbnail
Congress Presentation
Beyond stability: unveiling the prognostic and therapeutic role of serum transthyretin in amyloid cardiomyopathy
thumbnail
Congress Presentation
Outcome and disease progression in patients with wild-type transthyretin cardiomyopathy treated with tafamidis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources